Skip to main content
Journal cover image

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Publication ,  Journal Article
Reardon, DA; Wucherpfennig, KW; Freeman, G; Wu, CJ; Chiocca, EA; Wen, PY; Curry, WT; Mitchell, DA; Fecci, PE; Sampson, JH; Dranoff, G
Published in: Expert Rev Vaccines
June 2013

Outcome for glioblastoma (GBM), the most common primary CNS malignancy, remains poor. The overall survival benefit recently achieved with immunotherapeutics for melanoma and prostate cancer support evaluation of immunotherapies for other challenging cancers, including GBM. Much historical dogma depicting the CNS as immunoprivileged has been replaced by data demonstrating CNS immunocompetence and active interaction with the peripheral immune system. Several glioma antigens have been identified for potential immunotherapeutic exploitation. Active immunotherapy studies for GBM, supported by preclinical data, have focused on tumor lysate and synthetic antigen vaccination strategies. Results to date confirm consistent safety, including a lack of autoimmune reactivity; however, modest efficacy and variable immunogenicity have been observed. These findings underscore the need to optimize vaccination variables and to address challenges posed by systemic and local immunosuppression inherent to GBM tumors. Additional immunotherapy strategies are also in development for GBM. Future studies may consider combinatorial immunotherapy strategies with complimentary actions.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Vaccines

DOI

EISSN

1744-8395

Publication Date

June 2013

Volume

12

Issue

6

Start / End Page

597 / 615

Location

England

Related Subject Headings

  • Virology
  • Treatment Outcome
  • Immunotherapy
  • Humans
  • Glioblastoma
  • 3204 Immunology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Wucherpfennig, K. W., Freeman, G., Wu, C. J., Chiocca, E. A., Wen, P. Y., … Dranoff, G. (2013). An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines, 12(6), 597–615. https://doi.org/10.1586/erv.13.41
Reardon, David A., Kai W. Wucherpfennig, Gordon Freeman, Catherine J. Wu, E Antonio Chiocca, Patrick Y. Wen, William T. Curry, et al. “An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.Expert Rev Vaccines 12, no. 6 (June 2013): 597–615. https://doi.org/10.1586/erv.13.41.
Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun;12(6):597–615.
Reardon, David A., et al. “An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.Expert Rev Vaccines, vol. 12, no. 6, June 2013, pp. 597–615. Pubmed, doi:10.1586/erv.13.41.
Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun;12(6):597–615.
Journal cover image

Published In

Expert Rev Vaccines

DOI

EISSN

1744-8395

Publication Date

June 2013

Volume

12

Issue

6

Start / End Page

597 / 615

Location

England

Related Subject Headings

  • Virology
  • Treatment Outcome
  • Immunotherapy
  • Humans
  • Glioblastoma
  • 3204 Immunology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences